AXQ Capital
ALLO icon

AXQ Capital’s Allogene Therapeutics ALLO Stock Holding History

AXQ Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$141K Buy
88,010
+4,793
+6% +$9.12K 0.02% 821
2026
Q2 		$173K Buy
83,217
+9,287
+13% +$20.4K 0.02% 743
2026
Q1 		$180K Buy
+73,930
New +$148K 0.02% 775
2023
Q2 		– Sell
-16,750
Closed -$82.7K – 280
2023
Q1 		$82.7K Sell
16,750
-56,302
-77% -$361K 0.03% 458
2022
Q4 		$459K Buy
+73,052
New +$676K 0.32% 105

Other funds holding ALLO

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Pfizer
Pfizer New York $164M AUM 53.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

AXQ Capital's ALLO Position: Q3 2026 in Review

AXQ Capital increased its Allogene Therapeutics (ALLO) stake by 5.8% in Q3 2026, buying an estimated $9.12K and bringing the position to 88,010 shares worth $141K. The position accounts for 0.02% of the portfolio, ranked #821.

AXQ Capital first reported a position in ALLO in Q4 2022 and has held it in 5 quarters since. The position peaked at $459K in Q4 2022. 141 funds tracked by Wall St. Rank hold ALLO as of Q3 2026.

  • AXQ Capital held 88,010 shares of Allogene Therapeutics worth $141K as of Q3 2026.
  • AXQ Capital bought 4,793 Allogene Therapeutics shares in Q3 2026, an estimated $9.12K.
  • Allogene Therapeutics made up 0.02% of AXQ Capital's portfolio in Q3 2026, its #821 holding.
  • AXQ Capital first reported a position in Allogene Therapeutics in Q4 2022 and has held it in 5 quarters since.
  • AXQ Capital's Allogene Therapeutics position peaked at $459K in Q4 2022.
  • 141 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2026.

Based on AXQ Capital's 13F filing for Q3 2026, filed 12 Nov 2026.